相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma
Edward J. Gibson et al.
JOURNAL OF MEDICAL ECONOMICS (2019)
Modelled Economic Evaluation of Nivolumab for the Treatment of Second-Line Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer in Australia Using Both Partition Survival and Markov Models
Lan Gao et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2019)
Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England
D. Lee et al.
PHARMACOECONOMICS-OPEN (2019)
Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patients
Koen Degeling et al.
CANCER EPIDEMIOLOGY (2018)
Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling
Claire Williams et al.
MEDICAL DECISION MAKING (2017)
Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation
Eddie Gibson et al.
PHARMACOECONOMICS (2017)
Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer
Quang A. Le et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Structural Uncertainty of Markov Models for Advanced Breast Cancer: A Simulation Study of Lapatinib
Quang A. Le
MEDICAL DECISION MAKING (2016)
HOW TO MODEL SURVIVAL IN COST-EFFECTIVENESS ANALYSIS? DIFFERENCES BETWEEN MARKOV AND PARTITIONED SURVIVAL ANALYSIS MODELS
R. Minacori et al.
VALUE IN HEALTH (2015)
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
Don Husereau et al.
VALUE IN HEALTH (2013)
State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3
Uwe Siebert et al.
MEDICAL DECISION MAKING (2012)
Conceptualizing a Model: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2
Mark Roberts et al.
MEDICAL DECISION MAKING (2012)
A taxonomy of model structures for economic evaluation of health technologies
Alan Brennan et al.
HEALTH ECONOMICS (2006)
Bias in published cost effectiveness studies: systematic review
CM Bell et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
Analytic choices in economic models of treatments for rheumatoid arthritis: What makes a difference?
MF Drummond et al.
MEDICAL DECISION MAKING (2005)
分享论文
